Congratulations to David Koes and his collaborator Partha Roy! Their proposal to study small molecule inhibition of profilin was funded by CTSI.

Summary:

Our specific aim is to combine computationally-driven rational design with functional assays to discover potent and drug-like small molecules that interfere with the binding of profilin to actin and have anti-migratory and anti-angiogenic effects on endothelial cells. Successful completion of the proposed study will potentially translate to novel therapies for angiogenesis-associated diseases such as diabetic retinopathy, cancer, atherosclerosis, and arthritis.